Sacha Gnjatic mainly investigates Immunology, Antigen, Immune system, Cytotoxic T cell and Antibody. The concepts of his Immunology study are interwoven with issues in Cancer research and Melanoma. His Antigen research incorporates themes from Cancer and NY-ESO-1.
His Cancer study combines topics from a wide range of disciplines, such as Oncology and Bioinformatics. His research investigates the connection with Antibody and areas like Pathology which intersect with concerns in Follicular dendritic cells, Germinal center and Somatic hypermutation. His Cancer/testis antigens study in the realm of Immunotherapy connects with subjects such as Efficacy.
Sacha Gnjatic spends much of his time researching Immunology, Antigen, Immune system, Cancer research and Antibody. His Immunology study frequently intersects with other fields, such as Cancer. His work is dedicated to discovering how Cancer, Oncology are connected with Ovarian cancer and other disciplines.
Sacha Gnjatic has researched Antigen in several fields, including Cytotoxic T cell, Adjuvant and Cancer/testis antigens. He has included themes like Inflammation, Multiple myeloma and Bioinformatics in his Immune system study. The Cancer research study combines topics in areas such as Acquired immune system, Blockade and PD-L1.
Immune system, Cancer research, Internal medicine, Immunology and Multiple myeloma are his primary areas of study. Sacha Gnjatic works in the field of Immune system, namely Immunotherapy. His Cancer research research is multidisciplinary, incorporating perspectives in Acquired immune system, Cancer, PD-L1 and T cell.
His Internal medicine research integrates issues from Gastroenterology, Oncology and Coronavirus. Antigen and Autoantibody are the primary areas of interest in his Immunology study. Sacha Gnjatic interconnects Adjuvant and Antibody in the investigation of issues within Antigen.
Sacha Gnjatic mainly focuses on Internal medicine, Immune system, Antigen, Disease and Immunology. His studies in Internal medicine integrate themes in fields like Gastroenterology and Oncology. His Immune system study combines topics in areas such as Inflammation, Cancer and Cancer research.
His Antigen research integrates issues from Adjuvant, Antibody and NY-ESO-1. He has researched NY-ESO-1 in several fields, including Cancer/testis antigens, Melanoma and Sarcoma, Synovial sarcoma. His Disease study incorporates themes from Blockade, Coronavirus and Single-cell analysis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
Eiichi Sato;Sara H. Olson;Jiyoung Ahn;Brian Bundy.
Proceedings of the National Academy of Sciences of the United States of America (2005)
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Michael A. Postow;Margaret K. Callahan;Margaret K. Callahan;Christopher A. Barker;Christopher A. Barker;Yoshiya Yamada;Yoshiya Yamada.
The New England Journal of Medicine (2012)
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.
Naomi N. Hunder;Herschel Wallen;Jianhong Cao;Deborah W. Hendricks.
The New England Journal of Medicine (2008)
Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Junko Matsuzaki;Sacha Gnjatic;Paulette Mhawech-Fauceglia;Amy Beck.
Proceedings of the National Academy of Sciences of the United States of America (2010)
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses
Sacha Gnjatic;Djordje Atanackovic;Elke Jäger;Mitsutoshi Matsuo.
Proceedings of the National Academy of Sciences of the United States of America (2003)
Cancer classification using the Immunoscore: a worldwide task force.
Jérôme Galon;Franck Pagès;Francesco M Marincola;Francesco M Marincola;Helen K Angell;Helen K Angell.
Journal of Translational Medicine (2012)
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.
Elke Jäger;Sacha Gnjatic;Yasuhiro Nagata;Elisabeth Stockert.
Proceedings of the National Academy of Sciences of the United States of America (2000)
Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses
Yonit Lavin;Soma Kobayashi;Andrew Leader;El-ad David Amir.
Cell (2017)
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.
Ian D. Davis;Ian D. Davis;Weisan Chen;Heather Jackson;Phillip Parente;Phillip Parente.
Proceedings of the National Academy of Sciences of the United States of America (2004)
Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses
Elke Jäger;Yasuhiro Nagata;Sacha Gnjatic;Hisashi Wada.
Proceedings of the National Academy of Sciences of the United States of America (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
Ludwig Cancer Research
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Icahn School of Medicine at Mount Sinai
Cornell University
Icahn School of Medicine at Mount Sinai
Roswell Park Cancer Institute
University of Zurich
Memorial Sloan Kettering Cancer Center
Nagoya University
The Ohio State University
Boston University
Argonne National Laboratory
University of California, Berkeley
Northeast Normal University
University of Navarra
Imperial College London
University of Groningen
Emory University
Istanbul Technical University
Karlsruhe Institute of Technology
University of Michigan–Ann Arbor
New York University
Lund University
Newcastle University
Johns Hopkins University